Canopy Growth reports Q3 FY2025 revenue up 19% YoY, Canada medical cannabis up 16%.
ByAinvest
Friday, Feb 7, 2025 7:12 am ET1min read
CGC--
A significant highlight of Q3 FY2025 was the strong performance of Storz & Bickel. Net revenue grew by 19% year-over-year (YoY), reaching a record quarter for the company. The growth was attributed to the continued popularity of the company's vaporizer products, particularly during the holiday season.
Canada's medical cannabis market also experienced growth, with net revenue increasing by 16% YoY. International markets cannabis net revenue also saw a 14% YoY increase, reflecting the company's expanding global reach.
One of the most notable achievements during Q3 FY2025 was the successful launch of Claybourne infused pre-rolls across Canada. These pre-rolls quickly rose to the number three market share in the infused pre-roll category in British Columbia and Ontario after just six weeks in the market [1].
Despite the impressive revenue growth, Canopy Growth reported a net loss from continuing operations of $121,896 in Q3 FY2025. However, the company's adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 47% to $28,181 compared to Q3 FY2024. This improvement was attributed to strong top-line growth and continued cost discipline.
Looking ahead, Canopy Growth is focused on achieving sustainable profitability while maximizing its ability to create value in the key markets and segments it serves. With a strong financial position and a robust product portfolio, the company is well-positioned to capitalize on opportunities in the rapidly evolving cannabis market.
References:
[1] Canopy Growth Reports Third Quarter Fiscal Year 2025 Financial Results. (2025, February 7). Retrieved from https://www.marketscreener.com/quote/stock/CANOPY-GROWTH-CORPORATION-16195087/news/Canopy-Growth-Reports-Third-Quarter-Fiscal-Year-2025-Financial-Results-48993775/
STORJ--
• Canopy Growth reports Q3 FY2025 financial results • Strong holiday sales drive 19% YoY net revenue growth for Storz & Bickel • Canada medical cannabis net revenue increases 16% YoY • International markets cannabis net revenue grows 14% YoY • Successfully launched Claybourne infused pre-rolls in Canada • Claybourne rose to #3 market share in British Columbia and Ontario • Canopy Growth's Q3 FY2025 financial results to be reported in Canadian dollars.
Canopy Growth Corporation (CGC), a leading cannabis company based in Smiths Falls, Ontario, reported its financial results for the third quarter of fiscal year 2025 (Q3 FY2025) on February 7, 2025 [1]. The company's financial performance showcased robust growth, driven by the success of its medical cannabis business, Storz & Bickel, and the introduction of Claybourne infused pre-rolls in the Canadian market.A significant highlight of Q3 FY2025 was the strong performance of Storz & Bickel. Net revenue grew by 19% year-over-year (YoY), reaching a record quarter for the company. The growth was attributed to the continued popularity of the company's vaporizer products, particularly during the holiday season.
Canada's medical cannabis market also experienced growth, with net revenue increasing by 16% YoY. International markets cannabis net revenue also saw a 14% YoY increase, reflecting the company's expanding global reach.
One of the most notable achievements during Q3 FY2025 was the successful launch of Claybourne infused pre-rolls across Canada. These pre-rolls quickly rose to the number three market share in the infused pre-roll category in British Columbia and Ontario after just six weeks in the market [1].
Despite the impressive revenue growth, Canopy Growth reported a net loss from continuing operations of $121,896 in Q3 FY2025. However, the company's adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 47% to $28,181 compared to Q3 FY2024. This improvement was attributed to strong top-line growth and continued cost discipline.
Looking ahead, Canopy Growth is focused on achieving sustainable profitability while maximizing its ability to create value in the key markets and segments it serves. With a strong financial position and a robust product portfolio, the company is well-positioned to capitalize on opportunities in the rapidly evolving cannabis market.
References:
[1] Canopy Growth Reports Third Quarter Fiscal Year 2025 Financial Results. (2025, February 7). Retrieved from https://www.marketscreener.com/quote/stock/CANOPY-GROWTH-CORPORATION-16195087/news/Canopy-Growth-Reports-Third-Quarter-Fiscal-Year-2025-Financial-Results-48993775/

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet